Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Exome sequencing revealed C1Q homozygous mutation in Pediatric Systemic Lupus Er...
Journal Information
Vol. 46. Issue 6.
Pages 594-598 (November - December 2018)
Share
Share
Download PDF
More article options
Visits
767
Vol. 46. Issue 6.
Pages 594-598 (November - December 2018)
Original Article
Full text access
Exome sequencing revealed C1Q homozygous mutation in Pediatric Systemic Lupus Erythematosus
Visits
...
S. Zoghia, V. Ziaeeb,c, T. Hirschmugld,e, R. Jimenez-Herediad,e, A. Krolod,e, K. Boztugd,e,f,g, N. Rezaeia,h,i,
Corresponding author
rezaei_nima@tums.ac.ir

Corresponding author.
a Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
b Division of Pediatric Rheumatology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
c Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
d CeMM Research Center of Molecular Medicine, Austrian Academy of Sciences, and Division of Neonatal Medicine and Intensive Care, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria
e Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
f Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
g St Anna Kinderspital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Vienna, Austria
h Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
i Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Laboratory data of the patient at the age of two (after diagnosis) and three (one year after treatment) years old.
Table 2. List of homozygous rare variants (MAF<0.01) in the patient, which passed all the filtering steps.
Show moreShow less
Abstract
Introduction and objectives

Pediatric Systemic Lupus Erythematosus (pSLE) is an autoimmune disorder of children. Early disease onset raises the probability of genetic etiology and it is more severe than adult SLE.

Patients and methods

Herein an eight-year-old girl with pSLE from consanguineous parents is reported.

Results

Although she was diagnosed as pSLE since the age of two years, Whole Exome Sequencing (WES) revealed a rare stop-gained C>T mutation in C1QA gene. The variant was validated and segregated in patient and the family. Furthermore, serum levels of the C1q protein were measured and found to be much lower than normal ranges.

Conclusions

This study indicated that C1Q deficiency should be considered as a differential diagnosis of pSLE. Therefore, measurement of C1q should be recommended in all cases with pSLE.

Keywords:
Pediatric Systemic Lupus Erythematosus
Whole Exome Sequencing
C1Q deficiency
Full Text
Introduction

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease that affects many organs such as skin, kidneys and joints. About 10–20% of this autoimmunity occurs in children younger than 18 years, which refers as Pediatric SLE (pSLE). Compared to SLE in adults, the current knowledge on pSLE is scarce.1,2 pSLE usually occurs below 10–12 years of age and disease onset prior to this age has been rarely reported.3 Unfortunately, children affected by SLE have a worse course of disease and more devastating prognosis compared to adults.2 SLE complications such as nephritis, hematologic disorders, mucosal ulcers and skin rashes (butterfly rash) are more frequent in pediatric onset than adult onset of disease.2 Neuropsychiatric complications such as seizure and psychosis are reported in about 25% of patients and may be the first presenting manifestation of pSLE.4

Although the exact underlying pathogenesis of pSLE is not yet well understood, both genetic and environmental factors have been suggested to be important. Genetic defects are more likely to be seen in patients with pediatric early onset SLE compared to the adult onset form of the disease. This highlights the need for more investigations on possible genetic factors underlying pSLE that may be of value in both diagnostic and future therapeutic avenues.

It has previously been reported that SLE could be considered as a monogenic disorder in a proportion of cases, which occurs as a result of mutations in different genes.5 These genes are usually involved in different cellular pathways such as apoptosis, nucleic acid degradation and repair, B cell development, and pro-inflammatory cytokine pathways (i.e. IFN I); and they can affect normal tolerance. Autosomal recessive PRKCD and DNASE1L3 mutations have been reported as the causative gene defects in patients with pSLE.6,7 Additional genes that are involved in DNA degradation pathway such as TREX-1 and DNASE1 can cause autosomal dominant SLE with early age of onset.8,9 Other gene defects such as IFIH1 gain of function and ACP5 loss of function mutations were also reported to be the genetic causes of severe early-onset SLE.10,11 Early components of the complement system have also been reported to cause monogenic SLE-like syndrome.12 Here, we report a case of pSLE with C1Q mutation that occurred as early as 20 months of age.

MethodsSample preparation

Peripheral blood sample was collected from the patient with the consent of her parents. In addition to the patient, samples from parents and healthy sibling(s) were also collected; all family members signed informed consent before enrolment in the study. This study was approved by the Ethics Committee of Tehran University of Medical Sciences. Genomic DNA was extracted from all samples by standard phenol chloroform method. Serum samples were separated and kept in −70°C for further protein analysis.

Whole Exome Sequencing (WES)

TrueSeq Rapid Exome kit was used for genome library preparation, after cluster generation; sequencing was performed using Illumina HiSeq3000 platform. After sequencing, readings were aligned to the human genome version 19 using the Burrows-Wheeler Aligner (BWA). Variant annotation and functional effect prediction was performed using the SNPEFF tool. The variant list was then filtered according to the minor allele frequency (MAF) >0.01 in ExAC browser. Furthermore, an internal database was used to characterize recurrent variants. Finally, combined annotation dependent depletion (CADD) score was used for prediction of the effects of variants in order to prioritize them.13 Homozygosity mapping was performed by means of H3M2 (Homozygosity Heterogeneous Hidden Markov Model) software, which allows the detection of runs of homozygosity from whole-exome sequencing data.14

Evaluation of C1q serum level

In order to evaluate the serum level of C1q protein, an ELISA kit was used (Abcam, UK) according to the manufacturer's protocol.

ResultsPatient history

The case is an eight-year-old girl born from a consanguine Iranian family, who was primarily referred to Children's Medical Center hospital, a tertiary referral center affiliated to Tehran University of Medical Sciences at the age of two years. The patient started her first manifestation at the age of 20 months, by ataxic gait and imbalance. The gait disorder regressed in a period of four months, but her growth and development were completely normal before the disease onset. Furthermore, the patient experienced fever and seizure. Prolongation of fever, despite antibiotic therapy, led to some rheumatologic work ups, which revealed positive Anti-Nuclear Antibody (ANA). The patient gradually lost her walking and standing abilities, leading to walking disability at the time of her first admission. In physical examination, her extremity muscles were spastic. Later on, she developed malar rash and oral ulcers. Transverse myelitis was considered primarily as a potential reason for the patient's movement disorder; however, it was not proved since spinal magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis were normal. Electromyography (EMG) and nerve conduction velocity (NCV) were also performed for the patient in order to detect myopathy or neuropathy, which were normal as well.

In laboratory investigations, the patient had positive titer of Anti-dsDNA once in her medical record, which was not repeated again. C3 and C4 serum levels were normal. Her lab results are summarized in Table 1. The patient was hospitalized again at the age of three and six years, because of feet spasticity, skin lesions, painful oral ulcers, and alopecia.

Table 1.

Laboratory data of the patient at the age of two (after diagnosis) and three (one year after treatment) years old.

Parameter  2 years  3 years  Unit  Reference range 
WBC  13.8  6.88  103/μl  4–10 
RBC  4.7  4.68  106/μl  3.9–5.8 
HGB  13.1  13  g/dl  12–17 
HCT  38.4  38.3  36–53 
PLT  347  319  103/μl  150–450 
Neutrophil  30.6  55.2  20–50 
Lymphocyte  55.3  36.1  50–70 
Monocyte  13.7  8.1  2–8 
Eosinophil  0.2  0.3  0–6 
Basophil  0.2  0.3  0–1 
ESR  17  12  mm/h  0–10 
BUN  13.7  11  mg/dl   
Creatinine  0.6  0.6  mg/dl  0.5–1.4 
CPK  122  52  U/L  40–330 
AST  57  39  U/L  Up to 40 
ALT  101  36  U/L  Up to 40 
ALP  274  317  U/L  180–1200 
LDH  578  496  U/L  <850 
CRP  1.4  mg/L  <6 
ANA  2.89  1.8  index  <1.2 
Anti-ds DNA  23  27  U/ml  <100 
Anti-Phospholipid IgG  1.2  –  RU/ml  <12 
Anti-Phospholipid IgM  Neg  –  RU/ml  <12 
Anti-Cardiolipin IgG  3.9  Gplu/ml  <18 
Anti-Cardiolipin IgM  2.5  3.2  Mplu/ml  <18 
C3  150  87  mg/dl  90–18 
C4  27  17  mg/dl  10–40 
Urine protein  Neg  Neg    – 
Urine blood  Neg  Neg    – 
CSF culture  No growth after 72–    – 
CSF glucose  70  –  mg/dl  – 
CSF protein  10  –  mg/dl  – 

WBC: white blood cell, RBC: red blood cell, HGB: hemoglobin, HCT: hematocrit, PLT: platelet, ESR: erythrocyte sedimentation rate, BUN: blood urea nitrogen, CPK: creatinine phosphokinase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, LDH: lactate dehydrogenase, CRP: C reactive protein, ANA: anti-nuclear antibody.

She met the criteria of SLE according to the American College of Rheumatology (ACR) criteria and the diagnosis of SLE was made for the patient at the age of 2.15

Treatment

Treatment was started with methylprednisolone, hydroxychloroquine and gabapentin for the patient. For the feet spasticity, physiotherapy and hydrotherapy was started. She has had regular three months follow ups since then. The disease was under control; however, the treatment approaches had no improvement in the patient's walking disability. Abobotulinumtoxin A was injected to treat lower limb's muscle spasms in addition to multiple physiotherapy sessions, although none of them significantly improved the movement difficulties in the patient.

Genetic study

Analysis of the WES from the proband identified a rare (MAF<0.001) stop-gained C>T mutation (rs121909581) in the second coding exon of C1QA gene on chromosome 1. This mutation results in changing glutamine to stop codon at amino acid position 208 (Q208*), which is predicted to be deleterious by CADD score of 35. The variant was validated in the patient using PCR and Sanger sequencing method. Segregation using the DNA sample from the family was also performed by PCR and Sanger method which showed that both parents are heterozygous for the variant while the healthy sibling was homozygous for the wildtype allele (Fig. 1). Other homozygous variants with high prediction score were not immune related and could not describe the phenotype (Table 2).

Figure 1.

Chromatogram relate to Sanger validation and segregation of the mutation (chr1: 22965784 C>T) in patient, parents and healthy sibling.

(0.19MB).
Table 2.

List of homozygous rare variants (MAF<0.01) in the patient, which passed all the filtering steps.

Gene name  Chromosome  Position  REF  ALT  Function class  Amino acid change  CADD score 
C1QA  22965784  STOP_GAINED  Q208*  35 
ZSWIM5  45484952  MISSENSE  Y911C  21.6 
KLHL33  14  20897461  STOP_GAINED  Y383*  37 
MC1R  16  89985799  MISSENSE  F45L  23.9 
CLCN7  16  1497569  MISSENSE  V668M  19.57 

ZSWIM5; Zinc Finger SWIM-Type Containing 5, KLHL33; Kelch Like Family Member 33, MC1R; Melanocortin 1 Receptor, CLCN7; Chloride Voltage-Gated Channel 7.

C1q assay

The C1q protein level was very low in the patient (6.9μg/ml), comparing to the normal range of 156±36μg/ml in control group.

Discussion

Complement selective deficiencies have been reported as rare genetic disorders associated with lupus-like symptoms.12 Early components of complement classical pathway such as C1Q, C2 and C4 are reported to be associated with SLE.3C1Q mutations have been reported in few populations from Turkey, Sudan, Kosovo and Iraq in SLE affected families previously. A number of these mutations have been shown to be causative for SLE.16–18

C1q has a crucial role in innate immunity, and it is believed to be important in the innate-adaptive immunity crossroad. This glycoprotein belongs to collectin family and has molecular weight of 460,000KD. It consisted of 6 heterotrimeric chains; C1qA, B and C, which is encoded by three different gene on the short arm of chromosome 1. Each chain has a collagen like N-terminal and a globular C-terminal part, considered as the recognition domain which has ligand binding capability. Full length proteins of the A, B, and C are required to produce functional C1q protein.19 Although the exact mechanism of C1q involvement in SLE pathogenesis is not known, it is believed that C1q has an anti-inflammatory function in adaptive immunity. This anti-inflammatory function is done by helping to solubilize immune complexes in addition to clearance of apoptotic debris. Therefore, in the absence of this protein, apoptotic debris accumulates and triggers autoimmunity.20

Using WES, our pSLE patient showed to have a mutant C1QA, locating in the recognition domain of the protein which is very important for normal function of C1q complex. The mutation (Q208*) creates an early stop codon which possibly disturbs not only the structure of C1qA protein but also prevents the correct assembly of the whole C1q complex as confirmed by the low serum level of protein. The genetic analysis suggests that C1q deficiency resulted in SLE symptoms in the mentioned case of the present study. It has been shown that C1q binds to apoptotic debris and accelerates the clearance of debris (auto-antigens) which is very important to maintain tolerance.21

The present investigation discloses that monogenic immunodeficiency diseases such as C1q deficiency can explain the genetic etiology of a proportion of pSLE in Iranian population. Further investigations in the population are needed to elucidate the frequency of these genetic defects among the children affected by SLE.

Making an early diagnosis of C1q deficiency is challenging, while the features could be non-classic, compared to the majority of pSLE patients. In the presented patient, pSLE started with movement disorders, which was not accompanied by any joint, kidney, or heart involvement; the frequent clinical manifestations among pSLE cases in Iran (unpublished data). Former studies explained the criteria of C1q deficient patients as malar rash (in 95% of the cases), glomerulonephritis (42%), central nervous system (CNS) involvement (18%) in addition to high titers of autoantibodies (70%).21 However, our patient had similarities and differences with the mentioned features. According to our patient's history, the following combination could be considered as C1q deficient monogenic lupus as well; early onset (below the age of five), movement disorders (with poor response to treatment), skin manifestations (i.e. malar rash), and positive ANA.

Finally, we suggest that serum C1q level should be considered as a screening test in all pSLE cases, especially in those patients with disease onset below five years old and who suffer from movement problems. C1q serum level allows early diagnosis of C1Q deficient cases, which could be confirmed later by molecular methods, i.e. PCR and Sanger sequencing of all C1Q exons and help in finding the exact mutation in such patients.

Conflict of interest

The authors have no conflict of interest to declare.

Acknowledgements

This study was supported by Tehran University of Medical Sciences, Grant No. 95-01-30-31108. We thank Dr. Zahra Aryan for sharing her comments on the clinical presentation of the case.

References
[1]
M. Petri, A.M. Orbai, G.S. Alarcón, C. Gordon, J.T. Merrill, P.R. Fortin, et al.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Arthritis Rheumatol, 64 (2012), pp. 2677-2686
[2]
T. Tarr, B. Dérfalvi, N. Győri, A. Szántó, Z. Siminszky, A. Malik, et al.
Similarities and differences between pediatric and adult patients with systemic lupus erythematosus.
Lupus, 24 (2015), pp. 796-803
[3]
C. Malattia, A. Martini.
Paediatric-onset systemic lupus erythematosus.
Best Pract Res Clin Rheumatol, 27 (2013), pp. 351-362
[4]
A. Soybilgic.
Neuropsychiatric systemic lupus erythematosus in children.
Pediatr Ann, 44 (2015), pp. e153-e158
[5]
P. Costa-Reis, K.E. Sullivan.
Monogenic lupus: it's all new!.
Curr Opin Immunol, 49 (2017), pp. 87-95
[6]
A. Belot, P.R. Kasher, E.W. Trotter, A.P. Foray, A.L. Debaud, G.I. Rice, et al.
Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation.
Arthritis Rheum, 65 (2013), pp. 2161-2171
[7]
S.M. Al-Mayouf, A. Sunker, R. Abdwani, S.A. Abrawi, F. Almurshedi, N. Alhashmi, et al.
Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus.
Nat Genet, 43 (2011), pp. 1186-1188
[8]
J.I. Ellyard, R. Jerjen, J.L. Martin, A.Y. Lee, M.A. Field, S.H. Jiang, et al.
Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing.
Arthritis Rheumatol, 66 (2014), pp. 3382-3386
[9]
K. Yasutomo, T. Horiuchi, S. Kagami, H. Tsukamoto, C. Hashimura, M. Urushihara, Y. Kuroda.
Mutation of DNASE1 in people with systemic lupus erythematosus.
Nat Genet, 28 (2001), pp. 313-314
[10]
L. Van Eyck, L. De Somer, D. Pombal, S. Bornschein, G. Frans, S. Humblet-Baron, et al.
Brief report: IFIH1 mutation causes systemic lupus erythematosus with selective IgA deficiency.
Arthritis Rheumatol, 67 (2015), pp. 1592-1597
[11]
T.A. Briggs, G.I. Rice, S. Daly, J. Urquhart, H. Gornall, B. Bader-Meunier, et al.
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature.
Nat Genet, 43 (2011), pp. 127-131
[12]
M. Lewis, M. Botto.
Complement deficiencies in humans and animals: links to autoimmunity.
Autoimmunity, 39 (2006), pp. 367-378
[13]
M. Kircher, D.M. Witten, P. Jain, B.J. O'Roak, G.M. Cooper, J. Shendure, et al.
A general framework for estimating the relative pathogenicity of human genetic variants.
Nat Genet, 46 (2014), pp. 310-315
[14]
A. Magi, L. Tattini, F. Palombo, M. Benelli, A. Gialluisi, B. Giusti, et al.
H3M2: detection of runs of homozygosity from whole-exome sequencing data.
Bioinformatics, 30 (2014), pp. 2852-2859
[15]
M.C. Hochberg.
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
[16]
N. Gulez, F. Genel, F. Atlihan, B. Gullstrand, L. Skattum, L. Schejbel, et al.
Homozygosity for a novel mutation in the C1q C chain gene in a Turkish family with hereditary C1q deficiency.
J Investig Allergol Clin Immunol, 20 (2010), pp. 255-258
[17]
F. Petry, A.I. Berkel, M. Loos.
Multiple identification of a particular type of hereditary C1q deficiency in the Turkish population: review of the cases and additional genetic and functional analysis.
Hum Genet, 100 (1997), pp. 51-56
[18]
J.H. Slingsby, P. Norsworthy, G. Pearce, A.K. Vaishnaw, H. Issler, B.J. Morley, M.J. Walport.
Homozygous hereditary C1q deficiency and systemic lupus erythematosus: a new family and the molecular basis of C1q deficiency in three families.
Arthritis Rheumatol, 39 (1996), pp. 663-670
[19]
G. Sellar, D.J. Blake, K. Reid.
Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q.
Biochem J, 274 (1991), pp. 481-490
[20]
R.D. Sontheimer, E. Racila, D.M. Racila.
C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity.
J Invest Dermatol, 125 (2005), pp. 14-23
[21]
A.C. Macedo, L. Isaac.
Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway.
Front Immunol, 7 (2016), pp. 55
Copyright © 2018. SEICAP
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos